Post-Approved Phase III Study of 1-LV/5FU Therapy
Post-Approved Phase III Study of 1-LV/5FU Therapy
The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease-free survival time, survival time, and safety.
Inclusion Criteria:
Other inclusion applies
Exclusion Criteria:
Other exclusion applies